|
adult learning principles |
16 |
|
collaborative practice |
16 |
|
evaluation |
16 |
|
interprofessional education |
16 |
|
acupuncture |
11 |
|
analgesia |
9 |
|
randomized controlled trial |
9 |
|
alzheimer's disease |
8 |
|
apoptosis |
8 |
|
appswe/ps1de9 |
8 |
|
aquaporin 9 |
8 |
|
beta-amyloid |
8 |
|
health economic analysis |
7 |
|
morphine consumption |
7 |
|
pain |
7 |
|
placebo |
7 |
|
rct |
7 |
|
systematic review |
7 |
|
chemical constituent |
6 |
|
colorectal cancer |
6 |
|
cytotoxic activity |
6 |
|
electroacupuncture |
6 |
|
gleditsia sinensis |
6 |
|
leguminosae |
6 |
|
meta-analysis |
6 |
|
structural identification |
6 |
|
breast cancer |
5 |
|
chemotherapy-associated insomnia |
5 |
|
chinese herbal medicine |
5 |
|
chinese medicine |
5 |
|
diabetic nephropathy |
5 |
|
diet therapy |
5 |
|
fibrosis |
5 |
|
functional food |
5 |
|
inflammation |
5 |
|
knee osteoarthritis |
5 |
|
protocol |
5 |
|
review |
5 |
|
sham acupuncture |
5 |
|
sinew acupuncture |
5 |
|
smad7 |
5 |
|
acupoint |
4 |
|
acupuncture analgesia |
4 |
|
adiponectin |
4 |
|
adipor |
4 |
|
ampk |
4 |
|
auricular acupoint |
4 |
|
cessation rate of sleeping medications |
4 |
|
control |
4 |
|
covid-19 |
4 |
|
cytokine storm |
4 |
|
diabetic kidney disease |
4 |
|
immune response |
4 |
|
insomnia |
4 |
|
massage |
4 |
|
organ protection |
4 |
|
virus infection |
4 |
|
a549 non-small cell lung cancer cells |
3 |
|
acupressure |
3 |
|
akt/mtor |
3 |
|
arkadia |
3 |
|
auricular acupressure |
3 |
|
berberine |
3 |
|
chinese traditional |
3 |
|
cisplatin |
3 |
|
dendrobine |
3 |
|
diabetic retinopathy |
3 |
|
education |
3 |
|
guideline |
3 |
|
herbal medicine |
3 |
|
hif-1α |
3 |
|
insulin |
3 |
|
integrative medicine |
3 |
|
intervention |
3 |
|
intrapartum |
3 |
|
jnk/p38 signaling |
3 |
|
knee pain |
3 |
|
labor pain |
3 |
|
latent tgf-β1 |
3 |
|
medical |
3 |
|
medicine |
3 |
|
nf-κb |
3 |
|
osteoarthritis of the knee |
3 |
|
research methodology |
3 |
|
self-administered acupressure |
3 |
|
signaling pathway |
3 |
|
the university of hong kong |
3 |
|
traditional chinese medicine |
3 |
|
wait-list controlled |
3 |
|
adjunctive therapy |
2 |
|
akt3 |
2 |
|
antineoplastic agents - adverse effects - therapeutic use |
2 |
|
biosynthesis. |
2 |
|
chemotherapy, adjuvant |
2 |
|
chinese herbal medicine (chm) |
2 |
|
chronic heart failure |
2 |
|
chronic prostatitis/chronic pelvic pain syndrome |
2 |
|
colorectal neoplasms - drug therapy - mortality |
2 |
|
complementary and alternative medicine (cam) |
2 |
|
complementation of chinese and western medicine (中西醫學互補) |
2 |
|
direct moxibustion |
2 |
|
drugs, chinese herbal - therapeutic use |
2 |
|
essential oil |
2 |
|
estradiol. |
2 |
|
hepatic stellate cell |
2 |
|
herba asari |
2 |
|
herbs - china - therapeutic use. |
2 |
|
hu huanzhang (胡煥章) |
2 |
|
humans |
2 |
|
hypertensive nephropathy |
2 |
|
immunologic factors - therapeutic use |
2 |
|
indirect moxibustion |
2 |
|
inflammatory pain |
2 |
|
integration of chi-nese and western medicine (中西醫學結合) |
2 |
|
jingui yaolue |
2 |
|
liver fibrosis |
2 |
|
lung cancer |
2 |
|
medial philosophy (醫學哲學) |
2 |
|
medicine, chinese - formulae, receipts, prescriptions. |
2 |
|
menopause - treatment. |
2 |
|
mir-29b |
2 |
|
moxibustion |
2 |
|
neural-immune-endocrine interactions |
2 |
|
obstructive nephropathy |
2 |
|
outcome assessment (health care) |
2 |
|
overactive bladder |
2 |
|
petchiether a |
2 |
|
phytotherapy |
2 |
|
qiliqiangxin (qlqx) capsule |
2 |
|
quality of life |
2 |
|
renal fibrosis |
2 |
|
renal fibrosis and inflammation |
2 |
|
reviews |
2 |
|
smad |
2 |
|
stroke |
2 |
|
syndrome |
2 |
|
syndrome element |
2 |
|
syndrome questionnaire |
2 |
|
tgf-β |
2 |
|
tgf-β/smad3 |
2 |
|
treatise on exogenous febrile disease |
2 |
|
zhang zhongjing |
2 |
|
内伤 |
2 |
|
名醫經驗 |
2 |
|
和法 |
2 |
|
外感 |
2 |
|
治法 |
2 |
|
知常達變 |
2 |
|
胡煥章 |
2 |
|
脾胃病 |
2 |
|
脾胃病治法 |
2 |
|
辨证 |
2 |
|
/smads |
1 |
|
7-hydroxycoumarin |
1 |
|
ace2 |
1 |
|
aki |
1 |
|
alcohol |
1 |
|
alcoholic kidney injury |
1 |
|
analgesic effect |
1 |
|
ang ii |
1 |
|
angiotensin-converting enzyme-2 |
1 |
|
banxia xiexin decoction |
1 |
|
c-reactive protein |
1 |
|
cancer |
1 |
|
chinese herbal therapy |
1 |
|
chocolate cyst |
1 |
|
clinical predictor |
1 |
|
concomitant therapy |
1 |
|
crp |
1 |
|
cubilin |
1 |
|
diabetes |
1 |
|
diseases |
1 |
|
dna methylation |
1 |
|
drug |
1 |
|
embedment |
1 |
|
epigenetics |
1 |
|
fat mass and obesity-associated protein (fto) |
1 |
|
functional dyspepsia |
1 |
|
hazard ratio |
1 |
|
hepatocellular carcinoma |
1 |
|
histone modifications |
1 |
|
infection |
1 |
|
insulin resistance |
1 |
|
lung |
1 |
|
m(6)a |
1 |
|
megalin |
1 |
|
meridian |
1 |
|
meta analysis |
1 |
|
microrna |
1 |
|
microrna-21 |
1 |
|
mir-29 |
1 |
|
nadph oxidases |
1 |
|
nasopharyngeal carcinoma |
1 |
|
necroptosis |
1 |
|
nf-kb |
1 |
|
non-coding rnas |
1 |
|
nuclear factor κb (nf-κb) |
1 |
|
obesity |
1 |
|
ovarian endometriosis |
1 |
|
overactive bladder syndrome |
1 |
|
overweight |
1 |
|
oxidative stress |
1 |
|
parkinson’s disease |
1 |
|
peroxisome proliferator-activated receptor (ppar)-alpha(ppar-alpha) |
1 |
|
polyamine metabolism |
1 |
|
postprandial distress syndrome |
1 |
|
proliferation |
1 |
|
randomized controlled trials |
1 |
|
renal inflammation |
1 |
|
renin-angiotensin system |
1 |
|
rock |
1 |
|
sham control |
1 |
|
smad3 |
1 |
|
smad4 |
1 |
|
smoking |
1 |
|
smurf2 |
1 |
|
soft-tissue injury |
1 |
|
sp1 |
1 |
|
t1d |
1 |
|
t2d |
1 |
|
tgf-b1 signaling |
1 |
|
tgf-β receptor ii |
1 |
|
tgf-β signalling |
1 |
|
tgf-β/smad |
1 |
|
transcatheter arterial chemoembolization |
1 |
|
tubular cells, albuminuria |
1 |
|
ubiquitin |
1 |
|
uuo |
1 |
|
virus |
1 |
|
visual analogue scale |
1 |
|
wei-pi syndrome |
1 |
|
weight control |
1 |
|
療效 (efficacy) |
1 |
|
糖尿病 (diabetes) |
1 |
|
糖尿病胃輕癱 (diabetic gastroparesis) |
1 |
|
系統評價 (systematic review) |
1 |
|
針灸 (acupuncture) |
1 |
